fluorouracil and motexafin gadolinium

fluorouracil has been researched along with motexafin gadolinium in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ	1

Other Studies

1 other study(ies) available for fluorouracil and motexafin gadolinium

Article	Year
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Radiation oncology (London, England), 2012, Sep-13, Volume: 7 Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Kaplan-Meier Estimate; Male; Metalloporphyrins; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha	2012

Article

Year

Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.

Radiation oncology (London, England), 2012, Sep-13, Volume: 7

Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Kaplan-Meier Estimate; Male; Metalloporphyrins; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha

2012